AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AstraZeneca Tests Cancer Drug Mix for Safety and Drug Interactions
The study called “An Open-label, Fixed Sequence Phase I Study…” looks at how a common antifungal drug changes the way AstraZeneca’s new cancer drug moves through the body. It focuses on women with ovarian, primary peritoneal, or fallopian tube cancer and aims to guide safe dosing in real-world care.
The trial tests AZD5335, an antibody drug conjugate given by vein, designed to deliver a toxic payload directly to cancer cells. It also uses oral itraconazole, a strong antifungal, to see how this older drug affects levels of the cancer medicine.
This is an early stage treatment study with one treatment group and no placebo. Patients first receive AZD5335 alone and then get AZD5335 with itraconazole, with no blinding, so both doctors and patients know what is given.
The trial started in January 2026, marking the first use of this combination in this setting. The most recent update was posted on April 1, 2026, showing the design and timelines remain current while recruitment continues.
The main goal is to understand safety and drug interactions rather than to prove broad benefit, so the near-term impact on AZN’s revenue is limited. Still, a clean safety readout would support AstraZeneca’s wider oncology pipeline and keep investor sentiment positive versus peers also building out antibody drug conjugate platforms.
For now, the study remains active and updated, and investors can track future changes and outcomes on the ClinicalTrials portal.
To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.